Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2014
12/09/2014US8907068 Anti-IL-20 antibodies and binding partners and methods of using in inflammation
12/09/2014US8907064 Modified human four helical bundle polypeptides and their uses
12/09/2014US8907060 Mutated Pseudomonas exotoxins with reduced antigenicity
12/09/2014US8907058 PSMA binding ligand-linker conjugates and methods for using
12/09/2014US8906968 Process for bacterial stabilizing of aqueous ground natural calcium carbonate and/or precipitated calcium carbonate and/or dolomite and/or surface-reacted calcium carbonate-comprising mineral preparations
12/09/2014US8906956 Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
12/09/2014US8906907 Hypotensive lipid and timolol compositions and methods of using same
12/09/2014US8906903 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
12/09/2014US8906883 Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
12/09/2014US8906865 Treatment of inflammation and/or endotoxic shock
12/09/2014US8906855 Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
12/09/2014US8906847 Prodrug comprising a drug linker conjugate
12/09/2014US8906687 Blood brain barrier device
12/09/2014US8906676 Modified human four helical bundle polypeptides and their uses
12/09/2014US8906503 Fine particles of crystalline polyol, and method of preparing same
12/09/2014US8906421 Methods of dissolving blood clots and the like
12/09/2014US8906417 Nanostructures for drug delivery
12/09/2014US8906410 Oral dosage form of 25-hydroxyvitamin D
12/09/2014US8906409 Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylcholine
12/09/2014US8906406 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine
12/09/2014US8906405 Isotopically modified compounds and their use as food supplements
12/09/2014US8906403 Biomaterials carrying cyclodextrins having improved absorption properties and used for the progressive and delayed release of therapeutic molecules
12/09/2014US8906397 Permeation enhancers for topical formulations
12/09/2014US8906395 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved
12/09/2014US8906390 Synthetic lipid rafts and methods of use
12/09/2014US8906381 Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
12/09/2014US8906380 Fungal immunostimulatory compositions
12/09/2014US8906379 Targeting of glycoprotein therapeutics
12/09/2014US8906378 Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
12/09/2014US8906377 Stably tethered structures of defined compositions with multiple functions or binding specificities
12/09/2014US8906376 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
12/09/2014US8906368 Immunoglobulin preparations having increased stability
12/09/2014US8906355 Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof
12/09/2014US8906353 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
12/09/2014US8906345 Multimeric particles
12/09/2014US8906343 PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
12/09/2014US8906342 Compositions against cancer antigen LIV-1 and uses thereof
12/09/2014US8905997 Therapeutic particles suitable for parenteral administration and methods of making and using same
12/09/2014US8905913 Method and composition for synchronizing time of insemination
12/09/2014US8905235 Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
12/05/2014DE202012013134U1 Pharmazeutische Aerosolformulierung von Protease-Inhibitoren und deren Zubereitung A pharmaceutical aerosol formulation of protease inhibitors and their preparation
12/04/2014US20140357846 Thyroid stimulating hormone compositions
12/04/2014US20140357844 Antibodies specific for trop-2 and their uses
12/04/2014US20140357843 Immunoglobulin fc variants
12/04/2014US20140357731 Healing cream
12/04/2014US20140357729 Topical composition containing silicone base
12/04/2014US20140357723 Tricholine Nasal Formulation and Method of Use
12/04/2014US20140357709 Protective hydrocolloid for active ingredients
12/04/2014US20140357708 Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
12/04/2014US20140357657 Pharmaceutical Formulation Containing Gelling Agent
12/04/2014US20140357609 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
12/04/2014US20140357607 Corticosteroid compositions
12/04/2014US20140357600 Novel ester containing compositions and methods
12/04/2014US20140357591 Conjugated antimicrobial agents
12/04/2014US20140357586 Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions
12/04/2014US20140357574 Novel sustained release polymer
12/04/2014US20140357572 Neurotrophic peptides for the treatment of tauopathies
12/04/2014US20140357567 Methods for treating cancers using oral formulations of cytidine analogs
12/04/2014US20140357561 Natriuretic polypeptide delivery systems
12/04/2014US20140357559 Interpenetrating Polymer Network Hydrogel
12/04/2014US20140357557 Cyclodextrin-based polymers for therapeutic delivery
12/04/2014US20140357554 Magnesium Compositions for Modulating the Pharmacokinetics and Injection Site Pain of Insulin
12/04/2014US20140356930 Immune system enhancing immunotherapy for the treatment of cancer
12/04/2014US20140356467 Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof
12/04/2014US20140356465 Method of treatment using a therapeutic agent for intranasal administration
12/04/2014US20140356463 Process for obtaining citrus fiber from citrus peel
12/04/2014US20140356451 Polymer chelator conjugates
12/04/2014US20140356444 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
12/04/2014US20140356443 Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
12/04/2014US20140356440 Enteric Coated Multiparticulate Controlled Release Peppermint Oil Composition and Related Methods
12/04/2014US20140356438 Peripherally administered viscous formulations
12/04/2014US20140356435 Hydrophobic Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery Of A Drug-Delivery Composition
12/04/2014US20140356433 Pharmaceutical Carrier and Drug Structure Using the Same
12/04/2014US20140356429 Tablet containing ferric citrate
12/04/2014US20140356422 Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
12/04/2014US20140356421 Antibody-Conjugated Double-Emulsion Nanocapsule and Preparation Methods Thereof
12/04/2014US20140356418 Compositions for binding to amyloid proteins
12/04/2014US20140356417 Modified drugs for use in liposomal nanoparticles
12/04/2014US20140356414 Targeted Crosslinked Multilamellar Liposomes
12/04/2014US20140356399 Compositions and methods for treating viral infections
12/04/2014US20140356396 Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
12/04/2014US20140356385 Enzymatic conjugation of antibodies
12/04/2014US20140356383 Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer
12/04/2014US20140356382 Exosomes for Delivery of Biotherapeutics
12/04/2014US20140356376 Anti-wall teichoic antibodies and conjugates
12/04/2014US20140356375 Anti-wall teichoic antibodies and conjugates
12/04/2014US20140356367 Monophosphorylated lipid a derivatives
12/04/2014US20140356361 Repeated administration of non-immunosuppressive antigen specific immunotherapeutics
12/04/2014US20140356352 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
12/04/2014US20140356347 Novel serine protease variants
12/04/2014US20140356317 Cold Prepared Gel and Method for Making Same
12/04/2014US20140356315 Triblock copolymer and use therefor
12/04/2014US20140356314 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
12/04/2014US20140356294 Dosage that is safeguarded from abuse
12/04/2014US20140356293 Fluorescent compositions with enhanced fluorescence and methods based thereon
12/04/2014US20140356288 Topical Examination Compositions and Methods
12/04/2014US20140356286 Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3 Integrin
12/04/2014US20140356285 Compositions and methods related to tissue targeting
12/04/2014US20140356281 DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
12/02/2014USRE45272 β-glucuronide-linker drug conjugates
1 ... 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ... 1712